Cetera Investment Advisers
MBRX icon

Cetera Investment Advisers’s Moleculin Biotech MBRX Stock Holding History

Cetera Investment Advisers’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,800
Closed -$68.2K – 4168
2025
Q1 		$68.2K Buy
+2,800
New +$94.1K ﹤0.01% 3827

Other funds holding MBRX

Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cetera Investment Advisers's MBRX Position: Q2 2025 in Review

Cetera Investment Advisers sold out of Moleculin Biotech (MBRX) in Q2 2025, closing a stake of 2,800 shares — an estimated $68.2K sold.

Cetera Investment Advisers first reported a position in MBRX in Q1 2025 and held it in 1 quarter. The position peaked at $68.2K in Q1 2025. 21 funds tracked by Wall St. Rank hold MBRX as of Q2 2025.

  • Cetera Investment Advisers reported no remaining Moleculin Biotech position as of Q2 2025 after selling out during the quarter.
  • Cetera Investment Advisers sold 2,800 Moleculin Biotech shares in Q2 2025, an estimated $68.2K.
  • Cetera Investment Advisers first reported a position in Moleculin Biotech in Q1 2025 and held it in 1 quarter.
  • Cetera Investment Advisers's Moleculin Biotech position peaked at $68.2K in Q1 2025.
  • 21 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2025.

Based on Cetera Investment Advisers's 13F filing for Q2 2025, filed 8 Aug 2025.